Planned home birth presents little risk where midwifery is well-integrated
In the state of Washington, a planned home birth with a licensed midwife is just as safe as a birth at a licensed birth centre. Researchers from the… read more.
In the state of Washington, a planned home birth with a licensed midwife is just as safe as a birth at a licensed birth centre. Researchers from the… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Artesunate Amivas, intended for… read more.
EULAR President, Professor Annamaria Iagnocco, said: “EULAR is aware that more and more EU member states are experiencing shortages of essential anti-inflammatory drugs and that certain manufacturers have… read more.
Celltrion Healthcare announced two data sets relating to the use of the subcutaneous formulation of infliximab, Remsima SC (CT-P13 SC), in inflammatory bowel disease (IBD). The first study… read more.
People who live in cities face many challenges that threaten their mental health. In countries in which relatively higher numbers of people live in cities, depression, anxiety and… read more.
Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented at EADV’s 30th Congress. The findings of two studies are helping to advance… read more.
COVID-19 infection linked to increased risk of dangerous blood clots during surgery PrintEmail App Venous thromboembolism (VTE) is a condition in which dangerous blood clots form in the… read more.
Medtronic plc has announced new clinical data from the NAVABLATE study, which highlights the much anticipated safety and performance results on microwave ablation used bronchoscopically with the Emprint… read more.
Over 50 million people around the world suffer from dementia. Alzheimer’s disease is the most common form of dementia and is characterised by an accumulation of the proteins… read more.
Incyte announced that the FDA has approved Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12… read more.
UT Southwestern Medical Center An international panel of experts from four renowned diabetes research centers, including UT Southwestern Medical Center, has reviewed current literature and is recommending a… read more.
Deciphera Pharmaceuticals, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Qinlock… read more.